Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Adaptimmune Therapeutics PLC (ADAP) had Weighted-Average Shares Outstanding (Diluted) of 252.30M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$178.03M |
|
$-70.81M |
|
$0.07M |
|
$177.96M |
|
$246.79M |
|
$-68.76M |
|
$1.52M |
|
$-67.24M |
|
$-67.24M |
|
$-70.81M |
|
$-70.81M |
|
$-70.81M |
|
$-70.81M |
|
$-68.76M |
|
$-57.53M |
|
252.30M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
252.30M |
$-0.30 |
|
$-0.30 |
|
| Balance Sheet Financials | |
$188.17M |
|
$31.31M |
|
$57.79M |
|
$245.96M |
|
$64.53M |
|
$50.24M |
|
$169.59M |
|
$234.11M |
|
$11.85M |
|
$7.97M |
|
$11.85M |
|
255.94M |
|
| Cash Flow Statement Financials | |
$-73.21M |
|
$-58.95M |
|
$78.75M |
|
$147.02M |
|
$93.21M |
|
$-53.81M |
|
$12.05M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.92 |
|
-- |
|
-- |
|
0.81 |
|
4.24 |
|
99.96% |
|
-38.62% |
|
-38.62% |
|
-32.32% |
|
-37.77% |
|
-39.78% |
|
$-74.09M |
|
-- |
|
-- |
|
-- |
|
0.72 |
|
0.01 |
|
122.44 |
|
2.98 |
|
-597.64% |
|
-888.62% |
|
-28.79% |
|
-114.06% |
|
$0.05 |
|
$-0.29 |
|
$-0.29 |
|